The ASX 200 index is home to 200 of the largest listed companies on the Australian share market.
While there are a good number of quality options on offer in the index, two that could be in the buy zone are listed below.
Here's what you need to know about these ASX 200 shares:
Image source: Getty Images
CSL Limited (ASX: CSL)
The first blue chip ASX 200 share to look at is CSL. It is one of the world's leading biotherapeutics companies.
CSL has been a very positive performer over the last decade thanks to successful acquisitions, its high level of investment in R&D activities, a growing plasma collection network, and its leading therapies and vaccines.
In respect to the latter, CSL's portfolio includes lucrative and life-saving products such as Privigen, Hizentra, Idelvion, and Afstyla. But management never rests on its laurels and invests heavily in its R&D each year. And when I say heavily, I mean it! Each year the company invests in the region of 10% to 12% of sales into these activities. This means that it invested over US$1 billion on R&D in FY 2022. This ensures that the company has a pipeline of lucrative potential products to stay ahead of the competition and drive future growth.
One broker that is particularly positive on the company is Citi. It currently has an add rating and $340.00 price target on its shares.
Goodman Group (ASX: GMG)
Another blue chip ASX 200 share to look at is Goodman Group. It is a leading integrated commercial and industrial property company.
Goodman has a world class portfolio of in-demand warehouses, large scale logistics facilities, and business and office parks. In fact, demand is so strong that it currently boasts an occupancy rate of 99%. This helped underpin solid like-for-like net property income (NPI) growth during the first quarter despite the tough operating environment.
Looking ahead, the company appears well-placed to benefit from tight market conditions and its significant development pipeline.
Goldman Sachs is a big fan of Goodman. It currently has an overweight rating and $24.20 price target on the company's shares.
